Insulatard Innolet (Insulin Human)

Insulin human binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that promote glucose uptake, glycogen synthesis and lipid storage while suppressing hepatic glucose production. The NPH (neutral protamine Hagedorn) component slows absorption, extending the insulin’s action to provide a basal effect for many hours after injection.

The dose of Insulatard Innolet is individualized and set by a qualified prescriber based on the patient’s blood‑glucose targets, body weight, diet, activity level and concurrent therapies. Patients should follow the dosing instructions provided by their healthcare professional and adjust only under medical supervision.

The pregnancy safety category for insulin human (NPH) is not definitively established. Insulin is generally considered the preferred glucose‑lowering therapy in pregnancy when needed, but the decision should be made by the treating obstetrician and endocrinologist after weighing potential benefits and risks. Breastfeeding mothers should also consult their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Insulatard Innolet. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Insulatard Innolet (NPH insulin) is a protamine‑combined formulation that offers a peak of action around 4‑12 hours and a duration of up to 18 hours, making it suitable for twice‑daily dosing. Compared with newer basal analogues such as glargine or degludec, NPH has a more pronounced peak and may require more frequent glucose monitoring, but it is often less expensive and widely available.

Insulatard Innolet should be stored in a refrigerator at 2‑8 °C, protected from light and kept in its original packaging. Do not freeze the product, and avoid shaking the vial. Once in use, the solution can be kept at room temperature (up to 25 °C) for a maximum of 28 days, after which any remaining product should be discarded.

Insulatard Innolet is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated with each dose to reduce the risk of lipodystrophy. Patients should be trained by a healthcare professional on proper injection technique, needle length selection and disposal of used sharps.

The most serious risks include severe hypoglycaemia, which can lead to seizures, loss of consciousness or even death if not promptly treated, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognising early signs of low blood glucose and have a rapid‑acting carbohydrate source readily available.

Insulatard Innolet should be avoided in individuals with a known hypersensitivity to insulin human, protamine or any excipients in the formulation. It is also contraindicated in patients with severe hypoglycaemia unawareness or those who cannot reliably monitor their blood glucose levels. Clinical judgment is required for patients with significant renal or hepatic impairment.